Metformin is known to decrease the proliferative capacity and clonogenicity of breast cancer cell lines, regardless of p53 status and the status of estrogen and ErbB2 (elsewhere also referred to as Her-2/neu) receptors [62]. Here, ERBB2 is linked to breast carcinoma.